ORIC Pharmaceuticals Announces Enozertinib (ORIC-114) Data Presentations at ESMO Asia Congress 2025

ORIC Pharmaceuticals will present data from its Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025. The mini-oral presentation will focus on data in previously treated patients with EGFR atypical mutant NSCLC, while the proffered paper oral presentation will focus on data in previously treated and treatment-naïve patients with EGFR exon 20 mutant NSCLC. The company will also host a conference call and webcast on December 6, 2025.